Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

Completed · Phase 2

Conditions studied: Schizophrenia

In brief

The purpose of this study is to test the safety and effectiveness of talnetant vs. risperidone vs. placebo in reducing positive and negative symptoms in acutely psychotic schizophrenia patients.

Key facts

Study ID

NCT00300963

Run by

GlaxoSmithKline

People needed

275

Starts

2004-12-01

Expected to finish

2005-10-01

Last updated by the study team

2013-02-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have schizophrenia which is not secondary to another medical condition or substance abuse.
• Require inpatient hospitalization.
• Women may enroll only if they are not of child-bearing potential OR are on a protocol-approved birth control method.

You may not qualify if…

• Subject is in their first episode of schizophrenia.
• Subject has other psychotic disorders or bipolar disorder.
• Subject has schizophrenia symptoms from taking another medicine or drug of abuse, or due to a general medical condition.
• Subject has a recent history of substance dependence, or tests positive for illicit drug.
• Subject has an unstable medical disorder, or any significant medical disorder including autistic disorder, organic brain disease, liver dysfunction, epilepsy or seizures, or is at increased risk of developing cerebrovascular problems like stroke.
• Subject has any significant abnormalities in any of the screening tests (ECGs, labs, physical examinations, etc.).
• Subject poses a current serious suicidal or homicidal risk.
• Subject has a positive pregnancy test, or is lactating or planning to become pregnant within one month of the study.
• Subject has recently or is currently participating in another clinical study.
• Subject is stabilized on their current schizophrenia treatment.
• Subject needs to take any of the medicines not permitted in the study, or has recently had ECT (electroconvulsive therapy) or TMS (transcranial magnetic stimulation).
• Subject was non-responsive to two or more adequate trials of antipsychotic treatments over the past 2 years.
• Subject has had an allergic or significant reaction to any of the study drugs, or can't take risperidone.

Where it is running

• GSK Investigational Site — Little Rock, Arkansas, United States
• GSK Investigational Site — Anaheim, California, United States
• GSK Investigational Site — Cerritos, California, United States
• GSK Investigational Site — Garden Grove, California, United States
• GSK Investigational Site — Glendale, California, United States
• GSK Investigational Site — National City, California, United States
• GSK Investigational Site — Oceanside, California, United States
• GSK Investigational Site — Pico Rivera, California, United States
• GSK Investigational Site — Rosemead, California, United States
• GSK Investigational Site — San Diego, California, United States
• GSK Investigational Site — Upland, California, United States
• GSK Investigational Site — Washington D.C., District of Columbia, United States
• GSK Investigational Site — North Miami, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — St Louis, Missouri, United States
• GSK Investigational Site — Clementon, New Jersey, United States
• GSK Investigational Site — Philadelphia, Pennsylvania, United States
• GSK Investigational Site — Austin, Texas, United States
• GSK Investigational Site — Irving, Texas, United States
• GSK Investigational Site — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.